COMPLETED

Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)

Conditions

Exercise Induced Bronchospasm Exercise Induced Asthma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Due to the lack of studies examining the impact of inspiratory muscle training (IMT) on the severity of exercise-induced bronchoconstriction (EIB) and exercise performance, the specific aim of this study is to assess the efficacy of flow-resistive IMT on EIB severity and symptoms, short-acting beta-2-agonist medication use, operating lung volumes, respiratory and limb locomotor muscle deoxygenation during constant-load cycling exercise, exertional dyspnea, and cycling time-trial performance.

Official Title

Effect of Flow-Resistive Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Cycling Time-Trial Performance

Quick Facts

Study Start:2022-02-10

Study Completion:2025-04-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT06336681

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 35 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Male and female, between the ages of 18 to 35 years. * Required to be a competitive recreational or college athlete and have at least 1-2 years of cycling or biking experience. * Body Mass Index (BMI) of 18.5 to 28 kg/m\^2 * Considered "moderately to highly active" by the International Physical Activity Questionnaire (IPAQ). * Have clinically treated mild to moderate persistent asthma and/or exercise-induced bronchoconstriction (EIB), with a resting forced expiratory volume in 1 second (FEV1) \> 65% of predicted. * A ≥ 10% drop in FEV1 after eucapnic voluntary hyperpnea (EVH). * Prescribed short-acting β2-agonists (SABAs) by a physician. * Comfortable not taking SABA before experimental visits.	* History of smoking or recreational smoking, cardiovascular disease, renal disease, neurological disease, and metabolic disease. * Currently taking asthma maintenance medications (e.g., corticosteroids and leukotriene modifiers) * Any injuries in the past 6 months. * Taking selective serotonin reuptake inhibitors (SSRI)'s (antidepressants and anxiety medication), attention-deficit hyperactivity disorder (ADHD) medication, and chronically consume pain medication (Aleve, Tylenol, cannabidiol (CBD), etc.). * Has had or is positive for COVID-19. * Resting blood pressure of \> 130 mmHg systolic or 90 mmHg diastolic. * Resting Pulse rate of \> 100 bpm. * Regularly consuming fish oil supplements or eating more then one fish meal per week

Inclusion Criteria

Exclusion Criteria

* Male and female, between the ages of 18 to 35 years.
* Required to be a competitive recreational or college athlete and have at least 1-2 years of cycling or biking experience.
* Body Mass Index (BMI) of 18.5 to 28 kg/m\^2
* Considered "moderately to highly active" by the International Physical Activity Questionnaire (IPAQ).
* Have clinically treated mild to moderate persistent asthma and/or exercise-induced bronchoconstriction (EIB), with a resting forced expiratory volume in 1 second (FEV1) \> 65% of predicted.
* A ≥ 10% drop in FEV1 after eucapnic voluntary hyperpnea (EVH).
* Prescribed short-acting β2-agonists (SABAs) by a physician.
* Comfortable not taking SABA before experimental visits.

* History of smoking or recreational smoking, cardiovascular disease, renal disease, neurological disease, and metabolic disease.
* Currently taking asthma maintenance medications (e.g., corticosteroids and leukotriene modifiers)
* Any injuries in the past 6 months.
* Taking selective serotonin reuptake inhibitors (SSRI)'s (antidepressants and anxiety medication), attention-deficit hyperactivity disorder (ADHD) medication, and chronically consume pain medication (Aleve, Tylenol, cannabidiol (CBD), etc.).
* Has had or is positive for COVID-19.
* Resting blood pressure of \> 130 mmHg systolic or 90 mmHg diastolic.
* Resting Pulse rate of \> 100 bpm.
* Regularly consuming fish oil supplements or eating more then one fish meal per week

Contacts and Locations

Principal Investigator

Tim Mickleborough, Ph.D.

PRINCIPAL_INVESTIGATOR

Indiana University

Study Locations (Sites)

School of Public Health-Bloomington

Bloomington, Indiana, 47405

United States

Collaborators and Investigators

Sponsor: Indiana University

Tim Mickleborough, Ph.D., PRINCIPAL_INVESTIGATOR, Indiana University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-10

Study Completion Date2025-04-30

Study Record Updates

Study Start Date2022-02-10

Study Completion Date2025-04-30

Terms related to this study

Additional Relevant MeSH Terms

Exercise Induced Bronchospasm
Exercise Induced Asthma